Express News | Aptevo Provided Details About Portfolio On Cancer Immunotherapy

BenzingaNov 22 08:37 ET

Sector Update: Health Care Stocks Advance Wednesday Afternoon

MT NewswiresNov 20 14:00 ET

Aptevo Therapeutics Shares Gain After First Dosed Patient in AML Trial Shows 90% Reduction in Leukemic Blasts

MT NewswiresNov 20 09:32 ET

Express News | Aptevo Therapeutics - Favorable Early Safety, Efficacy, Tolerability,Durability of Remission Data Informed Co's Ongoing Rainier Phase 1B/2 Trial

ReutersNov 20 08:39 ET

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

AccesswireNov 20 08:35 ET

Aptevo Therapeutics' Bispecific Antibody Meets Trial Endpoints

MT NewswiresNov 11 09:27 ET